SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Commercializing biomedical research through securitization techniques
15 references·14 citing·37 second hop
Commercializing biomedical research through securitization techniques (2012)Commercializing biomedical research throu…Financing Risk and Innovation (2016)Financing Risk and InnovationWhere Have All the IPOs Gone? (2013)Where Have All the IPOs Gone?Financial development and innovation: Cross-country evidence (2013)Financial development and inn…Reading About the Financial Crisis: A Twenty-One-Book Review (2012)Reading About the Financial C…This time is different: eight centuries of financial folly (2010)This time is different: eight…How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)How to improve R&D productivi…This Time Is Different (2009)This Time Is DifferentThis Time Is Different (2009)This Time Is DifferentLessons from 60 years of pharmaceutical innovation (2009)Lessons from 60 years of phar…The cost of biopharmaceutical R&D: is biotech different? (2007)The cost of biopharmaceutical…Economics of New Oncology Drug Development (2007)Economics of New Oncology Dru…Venture Capital and the Finance of Innovation (2006)Venture Capital and the Finan…Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)Estimating The Cost Of New Dr…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …Continuous-Time Finance. (1991)Continuous-Time Finance.Security design: A review (2024)Security design: A reviewMissing Novelty in Drug Development (2021)Missing Novelty in Drug Devel…Competition and R&D Financing: Evidence From the Biopharmaceutical Industry (2021)Competition and R&D Financing…A Brain Capital Grand Strategy: toward economic reimagination (2020)A Brain Capital Grand Strateg…Intelligent Classifier: a Tool to Impel Drug Technology Transfer from Academia to Industry (2018)Intelligent Classifier: a Too…Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)Barriers for Access to New Me…Just how good an investment is the biopharmaceutical sector? (2017)Just how good an investment i…Do actuaries believe in longevity deceleration? (2017)Do actuaries believe in longe…Financing Entrepreneurial Experimentation (2016)Financing Entrepreneurial Exp…Innovation and Entrepreneurship in Renewable Energy (2015)Innovation and Entrepreneursh…Innovation and Entrepreneurship in Renewable Energy (2015)Innovation and Entrepreneursh…Cost of Experimentation and the Evolution of Venture Capital (2015)Cost of Experimentation and t…The risks of risk aversion in drug regulation (2013)The risks of risk aversion in…Can Financial Engineering Cure Cancer? (2013)Can Financial Engineering Cur…Credit Booms Gone Bust: Monetary Policy, Leverage Cycles, and Financial Crises, 1870–2008 (2012)The European Sovereign Debt Crisis (2012)Populism and the economics of globalization (2018)Systemic Banking Crises Database II (2020)Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology (1996)The black swan: the impact of the highly improbable (2007)The productivity crisis in pharmaceutical R&D (2011)THE WORLD MEDICINES SITUATION 2011 (2011)Drug discovery in pharmaceutical industry: productivity challenges and trends (2012)Principles of Corporate Finance. (1981)Cost of innovation in the pharmaceutical industry (1991)Deconstructing the Drug Development Process: The New Face of Innovation (2010)The cost of drug development: A systematic review (2011)Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval (2017)Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery (1996)American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care (2009)A Proof for the Queuing Formula: L = λ W (1961)The Goal: A Process of Ongoing Improvement (1984)Can the pharmaceutical industry reduce attrition rates? (2004)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 (2020)Investigating Causal Relations by Econometric Models and Cross-spectral Methods (1969)Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment Equations (1991)Another look at the instrumental variable estimation of error-components models (1995)Does banking competition affect innovation? (2014)Can the green credit policy stimulate green innovation in heavily polluting enterprises? Evidence from a quasi-natural experiment in China (2021)Digital finance, green technological innovation and energy-environmental performance: Evidence from China's regional economies (2021)Optimal consumption and portfolio policies when asset prices follow a diffusion process (1989)Backward Stochastic Differential Equations in Finance (1997)An Engine, Not a Camera (2006)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Trust and Growth (2001)Exchange Arrangements Entering the Twenty-First Century: Which Anchor will Hold?* (2019)Corporate Immunity to the COVID-19 Pandemic (2020)Macroeconomic and bank-specific determinants of non-performing loans in Greece: A comparative study of mortgage, business and consumer loan portfolios (2011)Econometric measures of connectedness and systemic risk in the finance and insurance sectors (2012)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 2010How to improve R&D productivity: the pharmaceutical industry's grand challenge3,562 cited
  • 2009This Time Is Different3,448 cited
  • 2009This Time Is Different2,361 cited
  • 1991Continuous-Time Finance.1,788 cited
  • 2010This time is different: eight centuries of financial folly1,776 cited
  • 2013Financial development and innovation: Cross-country evidence1,709 cited
  • 2009Lessons from 60 years of pharmaceutical innovation1,207 cited
  • 2006Estimating The Cost Of New Drug Development: Is It Really $802 Million?906 cited
  • 2007The cost of biopharmaceutical R&D: is biotech different?517 cited
  • 2013Where Have All the IPOs Gone?515 cited
  • 2006Venture Capital and the Finance of Innovation392 cited
  • 2007Economics of New Oncology Drug Development348 cited
  • 2012Reading About the Financial Crisis: A Twenty-One-Book Review275 cited
  • 2016Financing Risk and Innovation264 cited

Cited by

  • 2018Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

159 cited
  • 2013The risks of risk aversion in drug regulation115 cited
  • 2021Missing Novelty in Drug Development106 cited
  • 2015Cost of Experimentation and the Evolution of Venture Capital93 cited
  • 2020A Brain Capital Grand Strategy: toward economic reimagination81 cited
  • 2017Just how good an investment is the biopharmaceutical sector?58 cited
  • 2016Financing Entrepreneurial Experimentation52 cited
  • 2013Can Financial Engineering Cure Cancer?52 cited
  • 2015Innovation and Entrepreneurship in Renewable Energy49 cited
  • 2021Competition and R&D Financing: Evidence From the Biopharmaceutical Industry46 cited
  • 2015Innovation and Entrepreneurship in Renewable Energy37 cited
  • 2024Security design: A review21 cited
  • 2017Do actuaries believe in longevity deceleration?15 cited
  • 2018Intelligent Classifier: a Tool to Impel Drug Technology Transfer from Academia to Industry9 cited